FindTrial
Sign In

The development of a Patient Decision Aid (PDA) and Patient Concerns Inventory (PCI) for people diagnosed with recurrent head and neck cancer (HNC)

The development of a Patient Concerns Inventory and Decision aid for patients with Recurrent HNC

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
ISRCTN
Registry ID
ISRCTN12129699
Enrollment
60
Registered
2026-03-26
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent head and neck cancer Cancer

Interventions

The project is a 24-month, multiple-methods study with two interlinked workstreams involving five key stages. Workstream 1 will develop a PDA in accordance with the systematic process proposed by the

Sponsors

Royal Marsden NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 110 Years

Inclusion criteria

Inclusion criteria: Eligibility Criteria: Workstream 1 (PDA HN-R) For patients to be eligible to participate in the development of the PDA HN-R in this study, a patient must meet all the following inclusion criteria: 1. Age 18 or above. 2. Competency to provide consent. 3. Adequate linguistic and cognitive skills to take part in an interview. 4. Biopsy-proven locoregionally rHNC. 5. Head and neck multidisciplinary team (HN-MDT) meeting discussion documenting > 1 potential management option. For healthcare professionals to be eligible to participate in the development of the PDA HN-R in this study, an HCP (surgeon, oncologist, allied health professional (AHP), nurse) must meet only the following inclusion criterion: A minimum of 5 years’ clinical experience in working with patients with rHNC. Eligibility Criteria: Workstream 2 (PCI HN-R) For patients to be eligible to participate in the development of the PDA HN-R in this study, a patient must meet all the following inclusion criteria: 1. Biopsy-proven locoregionally recurrent HNC. 2. Undergoing systemic treatment immunotherapy/chemotherapy/clinical trial of investigational agents) OR have undergone surgery and/or re-irradiation for HNC recurrence. For healthcare professionals to be eligible to participate in the development of the PDA HN-R in this study, an HCP (surgeon, oncologist, AHP, nurse) must meet only the following inclusion criterion: A minimum of 5 years’ clinical experience in working with patients with rHNC, as with the PDA.

Exclusion criteria

Exclusion criteria: Patients/ HCPs not meeting all of the inclusion criteria.

Countries

England, United Kingdom

Contacts

Public ContactSofia Georgopoulou
sofia.georgopoulou@rmh.nhs.uk+44 02073528171

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 17, 2026